Determinants of vascular function in patients with type 2 diabetes

Katerina K Naka1,2, Katerina Papathanassiou3, Aris Bechlioulis1,2, Nikolaos Kazakos1,2, Konstantinos Pappas1,2, Stelios Tigas1, Dimitrios Makriyiannis4, Agathocles Tsatsoulis3 and Lampros K Michalis1,2,5*

Abstract

Background: Type 2 diabetes mellitus (T2DM) is independently associated with an increased risk for cardiovascular diseases that is primarily due to the early development of advanced atherosclerotic vascular changes. The aim of our study was to investigate the predictors of vascular dysfunction in T2DM patients.

Methods: We studied 165 T2DM patients without known macrovascular or microvascular disease. Standard demographic (age, gender, cardiovascular risk factors, medications), clinical (body mass index, blood pressure) and laboratory (glucose, glycated hemoglobin, lipids, renal function) parameters were included in analyses. Brachial artery flow-mediated dilation (FMD), nitrate mediated dilation (NMD) and Carotid-Femoral Pulse Wave Velocity (PWV) were measured.

Results: Median age was 66 years and duration since T2DM diagnosis was 10 years, 70% were females and 79% hypertensives, while only 10% had a glycated hemoglobin <7%. FMD was positively associated with NMD (r 0.391, P < 0.001), while PWV was inversely associated with FMD (r -0.218, P = 0.014) and NMD (r -0.309, P < 0.001). Time since diagnosis of diabetes was the single independent predictor of FMD (β -0.40, P = 0.003). Increased age and fasting glucose and the presence of hypertension were independent predictors of decreased NMD (P < 0.001). Increased age and systolic blood pressure were independently associated with increased PWV (P < 0.001).

Conclusions: In T2DM patients, impairment of endothelium-dependent vasodilation was independently associated only with longer diabetes duration while no association with other established risk factors was found. Vascular smooth muscle dysfunction and increased arterial stiffness were more prominent in older T2DM patients with hypertension. Worse glycemic control was associated with impaired vascular smooth muscle function.

Keywords: Type 2 diabetes mellitus, Pulse wave velocity, Flow-mediated dilation, Nitrate-mediated dilation, Atherosclerosis

Background

Type 2 diabetes mellitus (T2DM) is independently associated with an increased risk for cardiovascular diseases (CVD) [1] that is primarily due to the early development of advanced atherosclerotic vascular changes [2]. Vascular endothelial and smooth muscle cell dysfunction as well as large arterial stiffness are considered to be markers of subclinical atherosclerosis with a significant prognostic role in high risk populations [3-10]. Endothelial dysfunction, as assessed by decreased endothelium-dependent flow-mediated dilation (FMD) of the brachial artery [11-19], and increased arterial stiffness, assessed by aortic pulse wave velocity (PWV) [7,20-22], have been previously demonstrated in patients with T2DM compared to controls. Whether vascular smooth muscle cell function, assessed by nitrate mediated dilation (NMD) of the brachial artery [11-13,15,16,18,23] is also affected in T2DM patients has been questioned in previous studies. The mechanisms underlying the association of T2DM with vascular dysfunction are considered to be complex. Classical cardiovascular risk factors (hypertension, dyslipidemia and smoking) may play a role, while diabetes-related parameters such as hyperglycemia, insulin resistance and obesity, and other associated emerging risk factors such as
inflammation, may also contribute to the impairment of arterial function indices in T2DM. The relative importance of these risk factors in the induction of vascular dysfunction in T2DM patients has not been well studied previously.

The aim of our study was to investigate the predictors of vascular function, as assessed by brachial artery FMD and NMD and carotid-femoral PWV in T2DM patients without known macrovascular or microvascular disease.

**Methods**

**Subjects**

A total of 165 patients with previously diagnosed type 2 diabetes mellitus were consecutively recruited from the Endocrinology outpatient clinics of the University Hospital and Hatzikosta General Hospital of Ioannina, Ioannina, Greece from 2007 to 2009. Diagnosis of type 2 diabetes mellitus was defined according to the American Diabetes Association and the European Association for the Study of Diabetes [24]. Eligible subjects were patients 40 – 80 years old, under stable treatment with oral antidiabetic medications (metformin, sulfonylureas) or/and insulin for at least 6 months prior to study enrollment. No patient was on thiazolidinedione therapy. The duration of diabetes was defined as time since T2DM diagnosis and was confirmed by the patients’ clinical records. Patients reporting a history of macrovascular disease (coronary artery, cerebrovascular, or peripheral vascular disease), microvascular disease (diabetic retinopathy, symptomatic neuropathy, proteinuria), chronic heart failure, liver disease (or abnormal liver enzymes at study entry), anemia, thyroid dysfunction or other endocrine diseases and alcoholism were excluded from the study.

The study was approved by the Ethics Committee of the Michaelidion Cardiac Center, University of Ioannina, Greece and informed consent was obtained from all patients. The study complies with the Declaration of Helsinki.

**Risk factor assessment**

All participants underwent a medical interview concerning disease and risk factor history and general use of medications. A physical examination was then performed including measurement of blood pressure, height and weight. Office blood pressure (BP) was measured in the sitting position after 5 min of rest (just before the assessment of arterial stiffness indices) using an automated brachial sphygmomanometer (Omron M7, Omron Healthcare Co, Kyoto, Japan), and the mean of three consecutive measurements by a trained operator was reported. Body mass index (BMI) was calculated as weight/height$^2$ (kg/m$^2$). The following definitions were used: hypertension; blood pressure (BP) >140/90 mmHg or use of any antihypertensive medications, hypercholesterolemia; low density lipoprotein cholesterol (LDL-c) >2.6 mmol/l (100 mg/dl) or use of lipid-lowering agents (statins). Patients who were smoking at the time of study or had stopped smoking during the last 12 months prior to the study were defined as current smokers.

**Laboratory investigations**

Serum fasting glucose was determined by the hexokinase method and HbA1c by a latex agglutination inhibition assay (Randox, UK). Serum total and high density lipoprotein (HDL-c) cholesterol and triglycerides were measured by an enzymatic colorimetric assay. All assays were performed using an Olympus 640 analyser (Olympus Diagnostica GmbH, Hamburg, Germany). LDL-c was calculated using the Friedewald formula: LDL-c = total cholesterol - HDL-c - (triglycerides/5). Serum and urine creatinine concentrations were measured using an enzymatic method. Urinary albumin was measured by a turbidimetric assay. Subsequently, urinary albumin-to-creatinine ratio was evaluated by assessment of urine albumin-to-creatinine ratio in a spot sample. Microalbuminuria was defined as urine albumin-to-creatinine ratio between 3.5 – 35 mg/mmol creatinine for at least 2 out of 3 consecutive measurements. The glomerular filtration rate (GFR) was calculated using the chronic kidney disease epidemiology collaboration (CKD-EPI) formula (ml/min/1.73 m$^2$) [25]. Serum high sensitivity C-reactive protein (hs-CRP) was measured using rate turbidimetry (IMMAGE Immunochemistry Systems and Calibrator 5 Plus, Beckman Coulter Inc, Fullerton, CA, USA).

**Vascular measurements**

All vascular studies were performed early in the morning with the subjects fasted and refrained from smoking for at least 14 h before the study. All measurements were taken in the supine position in a quiet, temperature controlled room (~22°C) after a 30-min period of rest. All studies were performed by the same operator who was unaware of the patient’s medical history.

**Assessment of endothelial and smooth muscle cell function in the brachial artery**

Endothelial function was assessed by measurement of endothelium-dependent flow-mediated dilation (FMD) in the right brachial artery in response to hand hyperaemia. FMD was measured as previously described [26] according to published guidelines [27]. Images of the brachial artery were acquired at baseline, during hand hyperaemia at 90 sec after deflation of a wrist cuff inflated to 300 mmHg for 5 min for measurement of FMD, and at 4 min after 400 μg of sublingual glyceryl trinitrate for measurement of endothelium-independent, nitrate-mediated vasodilatation (NMD). FMD and NMD were calculated as weight/height$^2$ (kg/m$^2$).
were calculated as the percent increase in diameter during hyperaemia and after nitrate administration respectively compared with the diameter at rest. Brachial artery blood flow was measured by continuous wave Doppler ultrasound system (Ultrasound ATL, HDI 5000, Bophell, WA, USA) and a 5–12 MHz transducer were used for optimal imaging of the brachial artery. Images were recorded on super-VHS videotape (VCR Panasonic AG-MD 835, Osaka, Japan) for off-line analysis. Measurement of brachial artery diameter was performed by another blinded operator, at end-diastole coincident with the R-wave on the electrocardiogram, using electronic calipers from the anterior to the posterior m-line at a fixed distance from an anatomic marker. Internal repeatability data of FMD and NMD measurements in our laboratory have been previously published [26].

Assessment of arterial stiffness
Arterial stiffness was assessed non-invasively with the commercially available SphygmoCor system (Version 7.01, At Cor Medical, Sydney, Australia) using applanation tonometry to measure carotid-femoral pulse wave velocity (PWV) as previously described [28]. Pressure waveforms were recorded from the carotid and femoral arteries. The distance travelled by the pulse wave was measured over the body surface as the distance between the two recording sites, and the distance from the suprasternal notch to the carotid was subtracted. Wave transit time (t) between the recording sites was calculated by the system software, using the R wave on the simultaneously recorded electrocardiogram as reference frame. PWV was calculated as distance/transit time. In studies performed on two separate days (8–12 days apart) in 12 subjects by a single operator, the within-subject coefficient of variation of PWV was 5.6%.

Statistical analysis
Continuous variables are presented as mean ± SD and categorical variables are shown as number (percentage, %). Kolmogorov–Smirnov Z-test was used to determine the normal distribution of continuous variables; age, diabetes duration and hs-CRP were not normally distributed. For not normally distributed variables data are presented as median (range). Univariate associations between FMD, NMD, PWV and other studied continuous variables) and Table 3 (categorical variables). In other studied parameters are shown in Table 2 (continuous variables). In multivariate analysis (Table 4), increased duration of diabetes was found to be the single independent predictor of decreased FMD (R^2 0.05, P = 0.003), while increased age and fasting glucose as well as the presence of hypertension were independent predictors of decreased NMD (R^2 0.16, P < 0.001). Increased age and SBP were independently associated with increased PWV (R^2 0.25, P < 0.001) (Table 4).

Discussion
In the current study in T2DM patients, indices of vascular function were found to be inter-related suggesting that they probably reflect overlapping pathophysiological aspects of the vascular atherosclerotic damage in T2DM patients. Further to this finding, markers of endothelial function (FMD), smooth muscle cell function (NMD) and large artery stiffness (PWV) were shown to share common correlates. Older age, longer duration of diabetes and treatment with insulin were associated with all markers of vascular dysfunction, although each marker...
Table 1 Characteristics of the studied population (n = 165)

| Demographics                     | Value       |
|----------------------------------|-------------|
| Age, years                       | 66 (40, 80) |
| Female gender, n (%)             | 116 (70)    |
| Time since diagnosis of diabetes, years | 10 (1, 33) |
| Smoking, n (%)                   | 28 (17)     |
| Hypertension, n (%)              | 131 (79)    |
| Antihypertensive medications, n (%) | 109 (66)   |
| ACE-I/ARBs                       | 84 (51)     |
| Calcium channel blockers         | 58 (35)     |
| Diuretics                        | 24 (15)     |
| Beta blockers                    | 13 (8)      |
| Hypercholesterolemia, n (%)      | 150 (91)    |
| Statins, n (%)                   | 48 (29)     |
| Oral antidiabetic medication, n (%) | 129 (78)   |
| Sulfonylureas                     | 98 (59)     |
| Metformin                        | 89 (54)     |
| Insulin treatment, n (%)         | 36 (22)     |
| Body mass index, kg/m²           | 30.1 ± 5.5  |

| Laboratory investigations        | Value       |
|----------------------------------|-------------|
| Fasting glucose, mmol/L          | 9.4 ± 2.7   |
| HbA1c, %                         | 8.3 ± 1.2   |
| Total cholesterol, mmol/L        | 5.6 ± 1.0   |
| HDL-c, mmol/L                    | 1.3 ± 0.3   |
| Triglycerides, mmol/L            | 1.7 ± 0.8   |
| LDL-c, mmol/L                    | 3.4 ± 0.9   |
| Creatinine, μmol/L               | 78.7 ± 17.7 |
| Glomerular filtration rate, ml/min/1.73 m² | 78.1 ± 16.3 |
| High sensitivity C-reactive protein, mg/l | 1.84 (0.31, 9.71) |
| Albumin to Creatinine ratio, mg/mmol | 1.20 (0.18, 34.50) |
| Microalbuminuria, n (%)          | 31 (19)     |

| Vascular measurements            | Value       |
|----------------------------------|-------------|
| Heart rate, beats/min            | 72 ± 11     |
| Systolic blood pressure, mmHg    | 146 ± 15    |
| Diastolic blood pressure, mmHg   | 78 ± 7      |
| Flow-mediated dilation, %        | 1.98 ± 1.66 |
| Nitrate-mediated dilation, %     | 10.09 ± 3.84|
| Carotid-femoral pulse wave velocity, m/sec | 10.2 ± 2.2 |

Continuous data are presented as mean ± SD. For not normally distributed variables (age, time since diagnosis of diabetes, high sensitivity C-reactive protein and urine albumin to creatinine ratio) data are presented as median (range). ACE-I, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers; HbA1c, glycated hemoglobin; HDL-c, high density lipoprotein cholesterol; LDL-c, low density lipoprotein cholesterol.

T2DM patients has been mainly attributed to vascular endothelial dysfunction [17]. In T2DM patients without macrovascular or microvascular disease, we found that endothelial dysfunction, as assessed by reduced brachial artery FMD, was independently associated only with the duration of diabetes; for every 10 years of diabetes, FMD is reduced by approximately 1.0% (in absolute FMD values). Previous studies have shown significant associations of FMD with diabetes duration [29,30] although not consistently [31]. Longer T2DM duration has also been shown to increase CVD risk and total mortality significantly even after adjustment for established and novel cardiovascular risk factors [32] suggesting that there might be a link between T2DM duration, worsening endothelial function and cardiovascular prognosis in these patients. Furthermore, we showed that impairment of endothelial function in T2DM patients was not related to the presence or levels of various established cardiovascular risk factors, vascular inflammation or glyemic control. In accordance with our findings previously reported data have not shown an association of glycemic control with endothelial dysfunction [31,33]. On the other hand, endothelial dysfunction has been previously related to the presence and levels of cardiovascular risk factors in T2DM patients [23,29,30], although not consistently [34], while vascular inflammation has been suggested to play a central role in the development of endothelial dysfunction [35]. It should be noted that compared to other reports [23,29,30], our study included T2DM patients with severely impaired FMD (mean FMD 1.98%) and a high prevalence of accumulated cardiovascular risk factors; in these patients longer duration of diabetes, and not other established cardiovascular risk factors, was the only important determinant of endothelial dysfunction. Diabetes duration may appear to be a more important contributor to endothelial dysfunction compared to indices of short-term glycaemic control or other isolated risk factors as it may reflect the total exposure of the endothelium to diabetes and hyperglycaemia (metabolic memory) [36] as well as other diabetes-related comorbidities (hypertension, dyslipidemia, obesity).

Vascular smooth muscle cell dysfunction has been previously shown in T2DM patients compared to healthy controls in addition to endothelial dysfunction [11,13,15,37] indicating that T2DM may both reduce the bioavailability of endothelial nitric oxide and attenuate smooth muscle cells’ sensitivity to nitric oxide; these findings have not been consistently replicated in all studies [12,16,18,23]. Vascular smooth muscle cell dysfunction has been previously reported in populations at high cardiovascular risk [38,39] and a prognostic role has been suggested in such individuals [4,10].
In our study, decreased NMD was independently associated with older age, the presence of hypertension and higher fasting glucose. Several previous studies have not shown any significant associations of NMD with risk factors, glycemic control, inflammation or other diabetes-related factors in T2DM patients [13,31]. In agreement with our findings, hyperglycemia was recently reported to be an independent predictor of reduced NMD.

### Table 2 Associations between vascular measurements (FMD, NMD and PWV) and other continuous parameters in univariate analysis

|                      | FMD, % |          | NMD, % |          | PWV, m/sec |          |
|----------------------|--------|----------|--------|----------|------------|----------|
|                      | *r*    | *P*      | *r*    | *P*      | *r*        | *P*      |
| *Age, years*         | −0.155 | 0.047    | −0.319 | <0.001   | 0.465      | <0.001   |
| *Time since diagnosis of diabetes, years* | −0.254 | 0.001    | −0.272 | <0.001   | 0.254      | 0.004    |
| Body mass index, kg/m² | 0.102  | 0.194    | 0.027  | 0.732    | −0.217     | 0.015    |
| Fasting glucose, mmoL/L | −0.124 | 0.113    | −0.196 | 0.011    | 0.024      | 0.793    |
| HbA1c, %             | −0.117 | 0.135    | −0.140 | 0.072    | 0.150      | 0.094    |
| Total cholesterol, mmoL/L | −0.058 | 0.459    | 0.082  | 0.297    | −0.131     | 0.142    |
| HDL-c, mmoL/L        | −0.101 | 0.197    | −0.005 | 0.952    | −0.053     | 0.555    |
| Triglycerides, mmoL/L | 0.028  | 0.724    | 0.066  | 0.397    | 0.034      | 0.702    |
| LDL-c, mmoL/L        | −0.041 | 0.597    | 0.068  | 0.386    | −0.143     | 0.110    |
| Glomerular filtration rate, ml/min/1.73 m² | 0.073  | 0.351    | 0.209  | 0.007    | −0.274     | 0.002    |
| *Albumin to Creatinine ratio, mg/mmol* | −0.052 | 0.607    | 0.025  | 0.808    | −0.013     | 0.907    |
| *High sensitivity C-reactive protein, mg/l* | 0.021  | 0.807    | −0.121 | 0.161    | 0.057      | 0.556    |
| Heart rate, beats/min | −0.014 | 0.856    | −0.067 | 0.393    | 0.089      | 0.323    |
| Systolic blood pressure, mmHg | −0.121 | 0.122    | −0.231 | 0.003    | 0.305      | 0.001    |
| Diastolic blood pressure, mmHg | 0.022  | 0.777    | −0.011 | 0.889    | 0.014      | 0.879    |

*Natural logarithm transformed variables. FMD, flow-mediated dilation of the brachial artery; HbA1c, glycated hemoglobin; HDL-c, high density lipoprotein cholesterol; LDL-c, low density lipoprotein cholesterol; NMD, nitrate-mediated dilation of the brachial artery; PWV, carotid-femoral pulse wave velocity.*

### Table 3 Associations of vascular measurements (FMD, NMD and PWV) with categorical parameters

|                      | FMD, % |          | NMD, % |          | PWV, m/sec |          |
|----------------------|--------|----------|--------|----------|------------|----------|
|                      | *P*    |          | *P*    |          | *P*        |          |
| Gender               |        |          |        |          |            |          |
| Male, n = 49         | 1.92 ± 1.56 | 10.32 ± 4.52 | 10.62 ± 2.54 |          |
| Female, n = 116      | 2.00 ± 1.71 | 0.772 | 9.99 ± 3.51 | 0.648 | 10.02 ± 2.09 | 0.181 |
| Smoking              |        |          |        |          |            |          |
| Yes, n = 28          | 2.01 ± 1.47 | 10.33 ± 4.07 | 10.31 ± 2.58 |          |
| No, n = 137          | 1.97 ± 1.70 | 0.900 | 10.04 ± 3.80 | 0.720 | 10.16 ± 2.18 | 0.793 |
| Hypertension         |        |          |        |          |            |          |
| Yes, n = 131         | 1.93 ± 1.65 | 9.58 ± 3.58 | 10.47 ± 2.24 |          |
| No, n = 34           | 2.14 ± 1.73 | 0.528 | 12.05 ± 4.19 | 0.001 | 9.25 ± 1.98 | 0.009 |
| Antihypertensive medications |        |          |        |          |            |          |
| Yes, n = 109         | 1.84 ± 1.64 | 9.09 ± 3.33 | 10.54 ± 2.12 |          |
| No, n = 56           | 2.24 ± 1.68 | 0.143 | 12.03 ± 4.05 | <0.001 | 9.57 ± 2.31 | 0.019 |
| Hypercholesterolemia |        |          |        |          |            |          |
| Yes, n = 150         | 1.94 ± 1.65 | 10.03 ± 3.86 | 10.19 ± 2.24 |          |
| No, n = 15           | 2.29 ± 1.77 | 0.441 | 10.63 ± 3.66 | 0.565 | 10.11 ± 2.23 | 0.911 |
| Statins              |        |          |        |          |            |          |
| Yes, n = 48          | 1.99 ± 1.65 | 9.88 ± 3.91 | 10.57 ± 2.45 |          |
| No, n = 117          | 1.97 ± 1.67 | 0.951 | 10.17 ± 3.82 | 0.656 | 10.01 ± 2.12 | 0.199 |
| Insulin treatment    |        |          |        |          |            |          |
| Yes, n = 36          | 1.53 ± 1.66 | 8.65 ± 3.01 | 11.12 ± 2.72 |          |
| No, n = 129          | 2.10 ± 1.65 | 0.066 | 10.49 ± 3.95 | 0.004 | 9.97 ± 2.06 | 0.059 |

*FMD, flow-mediated dilation of the brachial artery; NMD, nitrate-mediated dilation of the brachial artery; PWV, carotid-femoral pulse wave velocity.*
of impaired NMD in T1DM patients [40]. Hyperglycemia, by increasing advanced glycation end-products and oxidative stress in the vascular wall, may be associated with a decreased response of vascular smooth muscle cells [15,35].

Arterial stiffness, as assessed by PWV, has been found to be increased both in prediabetes [41] and in T2DM patients compared to healthy controls [7,20-22]. Increased PWV has been associated with a worse cardiovascular prognosis in high risk patients [3,5,6] including T2DM patients [7,9]. In the present study, increased PWV in T2DM patients was independently associated with older age and higher systolic blood pressure values confirming well established knowledge. Both age and blood pressure are considered to be the two most important determinants of PWV in the general population [42] as well as in T2DM patients [9,21]. In contrast to previous studies we found no association of PWV with glycemic control in T2DM patients [9,21,43,44]. Furthermore, although inflammation, as assessed by hs-CRP, has been suggested to related to increased PWV in healthy subjects [45] as well as in hypertensive [46] and T2DM [47] patients, this has not been replicated in our study.

Our population consisted of patients with T2DM with moderate glycaemic control and less than optimal control of other cardiovascular risk factors (blood pressure, cholesterol, obesity). These results cannot be extrapolated to all patients with T2DM; it is possible that including patients with optimal control of risk factors, important associations of risk factors with vascular indices may be revealed. Finally, whether interventions to improve these risk factors may have a beneficial effect on vascular indices has not been clarified in recent studies [34,48,49], and cannot be precluded from this study.

### Table 4 Determinants of vascular measurements (FMD, NMD and PWV) in multivariate analysis

|                      | Multivariate analysis |
|----------------------|-----------------------|
|                      | B (95% CI)       | P       |
| FMD, %               | Time since diagnosis of diabetes, years* | -0.40 (-0.66, -0.14) | 0.003 |
| NMD, %               | Age, years*        | -5.66 (-9.49, -1.82) | 0.004 |
|                      | Hypertension       | -1.80 (-3.25, -0.35) | 0.015 |
|                      | Fasting glucose, μmol/L | -0.36 (-0.54, -0.18) | 0.005 |
| PWV, m/sec           | Age, years*        | 6.22 (3.81, 8.63) | <0.001 |
|                      | Systolic blood pressure, mmHg | 0.03 (0.00, 0.05) | 0.032 |

*Natural logarithm transformed variables. FMD, flow-mediated dilation of the brachial artery; NMD, nitrate-mediated dilation of the brachial artery; PWV, carotid-femoral pulse wave velocity.

The independent variables included in the stepwise model were parameters whose association with the vascular parameters achieved statistical significance (P < 0.05) and other factors that may affect endothelial dysfunction and arterial stiffness (age, gender, heart rate, systolic blood pressure and use of antihypertensive medications).

Study limitations

This was an observational study that could not reveal causal relationships. Furthermore, regression models in our study could predict a small part of the variability of vascular indices (5–25%) in our population indicating that other factors, not currently studied (e.g. insulin resistance, advanced glycation end-products, genetic factors) may play a more important role in vascular dysfunction in T2DM. Common insulin resistance/sensitivity indices were not assessed because a high proportion of the studied patients were receiving exogenous insulin.

### Conclusion

In conclusion, in T2DM patients without known macrovascular or microvascular disease, impairment of endothelial-dependent vasodilation was independently associated only with longer diabetes duration while no association with other established risk factors known to be related to endothelial function was found. On the other hand, vascular smooth cell dysfunction and increased arterial stiffness were more prominent in older T2DM patients with hypertension. Worse glycemic control was only associated with impaired vascular smooth muscle cell function. Further studies are needed to investigate the clinical and prognostic implications of our findings.

### Abbreviations

T2DM: Type 2 diabetes mellitus; CVD: Cardiovascular diseases; FMD: Flow-mediated dilation; PWV: Pulse wave velocity; NMD: Nitrate-mediated dilation; BMI: Body mass index; BP: Blood pressure; LDL-c: Low density lipoprotein cholesterol; HDL-c: High density lipoprotein cholesterol; GFR: Glomerular filtration rate; hs-CRP: High sensitivity C-reactive protein.

### Competing interests

The authors declare that they have no competing interest.

### Authors’ contributions

KKN participated in the overall design, statistical analysis, data interpretation, writing and presentation of this work. KP participated in the overall design and conduct of the study, data collection and drafted portions of the manuscript. AB performed statistical analysis and contributed to the interpretation of data, writing and presentation of this work. NK participated in data collection, data collection and drafted portions of the manuscript. KP participated in the design of the study, data interpretation and critically revised the manuscript before final approval. ST participated in data interpretation and critically revised the manuscript before final approval. DM participated in study design, data collection and data interpretation. AT participated in study design, data collection, data interpretation and critically revised the manuscript before final approval. All authors read and approved the final manuscript.

### Author details

1. Michaelidion Cardiac Center, University of Ioannina, Ioannina, Greece.
2. Department of Cardiology, University of Ioannina, Ioannina, Greece.
3. Department of Endocrinology, University of Ioannina, Ioannina, Greece.
4. Department of Endocrinology, Hatzikosta General Hospital, Ioannina, Greece.
5. Department of Cardiology and Michaelidion Cardiac Centre, University of Ioannina, Ioannina, Greece.

### Abbreviations

- FMD: Flow-mediated dilation
- NMD: Nitrate-mediated dilation
- PWV: Pulse wave velocity
- T2DM: Type 2 diabetes mellitus
- CVD: Cardiovascular diseases
- BMI: Body mass index
- BP: Blood pressure
- LDL-c: Low density lipoprotein cholesterol
- HDL-c: High density lipoprotein cholesterol
- GFR: Glomerular filtration rate
- hs-CRP: High sensitivity C-reactive protein
- NMD: Nitrate-mediated dilation
- PWV: Pulse wave velocity
- FMD: Flow-mediated dilation
- BMI: Body mass index
- BP: Blood pressure
- LDL-c: Low density lipoprotein cholesterol
- HDL-c: High density lipoprotein cholesterol
- GFR: Glomerular filtration rate
- hs-CRP: High sensitivity C-reactive protein

### Competing interests

The authors declare that they have no competing interest.

### Authors’ contributions

KKN participated in the overall design, statistical analysis, data interpretation, writing and presentation of this work. KP participated in the overall design and conduct of the study, data collection and drafted portions of the manuscript. AB performed statistical analysis and contributed to the interpretation of data, writing and presentation of this work. NK participated in data collection, data collection and drafted portions of the manuscript. KP participated in the design of the study, data interpretation and critically revised the manuscript before final approval. ST participated in data interpretation and critically revised the manuscript before final approval. DM participated in study design, data collection and data interpretation. AT participated in study design, data collection, data interpretation and critically revised the manuscript before final approval. All authors read and approved the final manuscript.

### Author details

1. Michaelidion Cardiac Center, University of Ioannina, Ioannina, Greece.
2. Department of Cardiology, University of Ioannina, Ioannina, Greece.
3. Department of Endocrinology, University of Ioannina, Ioannina, Greece.
4. Department of Endocrinology, Hatzikosta General Hospital, Ioannina, Greece.
5. Department of Cardiology and Michaelidion Cardiac Centre, University of Ioannina, Ioannina, Greece.
Naka et al. Cardiovascular Diabetology 2012, 11:127
http://www.cardiab.com/content/11/1/127
Page 7 of 8

Received: 12 August 2012 Accepted: 6 September 2012
Published: 12 October 2012

References
1. Englelguaj MM, Geiss LS, Saaddine JB, Boyle JP, Benjamin SM, Gregg EW, Tiemeley EF, Rios-Burrowes N, Mokdad AH, Ford ES, Imperatore G, Narayan KM: The evolving diabetes burden in the United States. Am Int Med 2004, 140:945–950.
2. Scholte AJ, Schuijf JD, Kharagjitsingh AV, Jukema JW, Pundziute G, van der Wall EE, Bax JJ: Prevalence of coronary artery disease and plaque morphology assessed by multi-slice computed tomography coronary angiography and calcium scoring in asymptomatic patients with type 2 diabetes. Heart 2008, 94:290–295.
3. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM: Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999, 99:2434–2439.
4. Schachinger V, Britten MB, Zeiher AM: Advanced glycation end products and microvascular complications in diabetes mellitus. Diabet Res Clin Pract 2002, 59:93–101.
5. Sun Y, Liu XM, Wang YY, Luan Y, Wu Y: Endothelial dysfunction in type 2 diabetes: the Hoom Study. Antioxid Thromb Vasc Biol 2006, 26:1086–1093.
6. Su Y, Liu XM, Sun YM, Wang YY, Luan Y, Wu Y: Endothelial dysfunction in impaired fasting glycemia, impaired glucose tolerance, and type 2 diabetes mellitus. Am J Cardiol 2008, 102:497–498.
7. Lyse H, Lynyn Z, Guangyao S, Luping R: Investigation of early change of endothelial function and related factors in individuals with hyperglycemia. Diabetes Res Clin Pract 2011, 92:94–97.
8. Luik E, Mitas Z, Boaz M, Sharogradsky M: Increasing derangement of glucose homeostasis is associated with increased arterial stiffness in patients with diabetes, impaired fasting glucose and normal controls. Diabetes Metab Res Rev 2010, 26:365–370.
9. Huyssou G, Pietri P, Machopoulos C, Alexopoulos N, Kyvelou SM, Tenentes-Printzos D, Stefanidis C: Early adverse effect of abnormal glucose metabolism on arterial stiffness in drug naive hypertensive patients. Diab Vasc Dis Res 2011, 9:18–24.
10. Zhang M, Bai Y, Ye P, Luo L, Xiao W, Wu H, Liu D: Type 2 diabetes is associated with increased pulse wave velocity measured at different sites of the arterial system but not augmentation index in a Chinese population. Clin Cardiol 2011, 34:622–627.
11. Tsuchiya K, Nakaoyama C, Iwashima F, Saki H, Izuymiya H, Doh M, Hirata Y: Advanced endothelial dysfunction in diabetic patients with multiple risk factors; importance of insulin resistance. J Atheroscler Thromb 2007, 14:303–309.
12. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin RM, Zinman B: Management of hyperglycemia in type 2 diabetes: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006, 49:1711–1721.
13. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lenten F, Greene T, Coresh J: A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604–612.
14. Papathanasiou K, Naka KK, Kazakos N, Kanioglu C, Makryliani D, Pappas K, Katsouras CS, Lieris K, Koletti T, Tsatsoulias A, Michalis LK: Pioglitazone vs gliptine: differential effects on vascular endothelial function in patients with type 2 diabetes. Atherosclerosis 2009, 205:221–226.
15. Conetti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita JA, Vogel R: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002, 39:257–265.
16. Vlahos AP, Theoraris P, Bechlioulis A, Naka KK, Vakalis K, Papamichael ND, Alfantis T, Gartzonika V, Magrini A, Michalis LK, Stamopoulos A: Changes in vascular function and structure in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011, 63:1736–1744.
17. Yokoyama H, Sone H, Saito K, Yamada D, Honjo J, Haneeda M: Flow-mediated dilation is associated with microalbuminuria independent of cardiovascular risk factors in type 2 diabetes – interrelations with arterial thickness and stiffness. J Atheroscler Thromb 2011, 18:744–752.
18. Beihunieden ED, Tamisna JT, Jukema JW, van de Ree MA, van der Vlijer JC, Meinders AE, Huisman MV: The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease. Diabetes Care 2005, 28:1668–1674.
19. Tan KC, Ai VH, Chow WS, Chau MT, Leong L, Lam KS: Influence of low density lipoprotein (LDL) subfraction profile and LDL oxidation on endothelial-dependent and independent vasodilation in patients with type 2 diabetes. J Clin Endocrinol Metab 1999, 84:3212–3216.
20. Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N: Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med 2011, 171:404–410.
21. Bogg W, Whalley GA, Gambare G, Drury PL, Sharpe N, Braund GD: Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes. Intern Med J 2001, 31:322–328.
22. Barone Gibbs B, Dobrosielski DA, Bonekamp S, Stewart KJ, Clark JW: A randomized trial of exercise for blood pressure reduction in type 2 diabetes: effect on flow-mediated dilation and circulating

Advanced endothelial dysfunction in diabetic patients with multiple risk factors; importance of insulin resistance. J Atheroscler Thromb 2007, 14:303–309.

16. Vlahos AP, Theoraris P, Bechlioulis A, Naka KK, Vakalis K, Papamichael ND, Alfantis T, Gartzonika V, Magrini A, Michalis LK, Stamopoulos A: Changes in vascular function and structure in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011, 63:1736–1744.

Yokoyama H, Sone H, Saito K, Yamada D, Honjo J, Haneeda M: Flow-mediated dilation is associated with microalbuminuria independent of cardiovascular risk factors in type 2 diabetes – interrelations with arterial thickness and stiffness. J Atheroscler Thromb 2011, 18:744–752.

Beihunieden ED, Tamisna JT, Jukema JW, van de Ree MA, van der Vlijer JC, Meinders AE, Huisman MV: The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease. Diabetes Care 2005, 28:1668–1674.

Tan KC, Ai VH, Chow WS, Chau MT, Leong L, Lam KS: Influence of low density lipoprotein (LDL) subfraction profile and LDL oxidation on endothelial-dependent and independent vasodilation in patients with type 2 diabetes. J Clin Endocrinol Metab 1999, 84:3212–3216.

Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N: Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med 2011, 171:404–410.

Bogg W, Whalley GA, Gambare G, Drury PL, Sharpe N, Braund GD: Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes. Intern Med J 2001, 31:322–328.

Barone Gibbs B, Dobrosielski DA, Bonekamp S, Stewart KJ, Clark JW: A randomized trial of exercise for blood pressure reduction in type 2 diabetes: effect on flow-mediated dilation and circulating
biomarkers of endothelial function. Atherosclerosis 2012, doi:10.1016/j.atherosclerosis.2012.07.035.

35. Schalkwijk CG, Stehouwer CD: Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond) 2005, 109:143–159.

36. Jax TW: Metabolic memory: a vascular perspective. Cardiovasc Diabetol 2010, 9:51.

37. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA: Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1998, 32:123–127.

38. Zhang X, Zhao SP, Li XP, Gao M, Zhou QC: Endothelium-dependent and -independent functions are impaired in patients with coronary heart disease. Atherosclerosis 2000, 149:19–24.

39. Bjarnegard N, Arnqvist HJ, Lindstrom T, Jonasson L, Jonsson A, Lanne T: Long-term hyperglycaemia impairs vascular smooth muscle cell function in women with type 1 diabetes mellitus. Diab Vasc Dis Res 2009, 6:25–31.

40. Shin JY, Lee HR, Lee DC: Increased arterial stiffness in healthy subjects with high-normal glucose levels and in subjects with pre-diabetes. Cardiovasc Diabetol 2011, 10:30.

41. Collaboration RVfAS: Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J 2010, 31:2338–2350.

42. Gomez-Marcos MA, Recio-Rodriguez JJ, Patino-Alonso MC, Agudo-Conde C, Gomez-Sanchez L, Rodriguez-Sanchez E, Gomez-Sanchez M, Garcia-Ortiz L: Relationships between high-sensitive C-reactive protein and markers of arterial stiffness in hypertensive patients. Differences by sex. BMC Cardiovasc Disord 2012, 12:37.

43. Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockcroft JR, Wilkinson IB: C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol 2004, 24:969–974.

44. Goméz-Marco MA, Recio-Rodriguez JJ, Patino-Alonso MC, Agudo-Conde C, Goméz-Sanchez L, Rodriguez-Sanchez E, Goméz-Sanchez M, Martinez-Vicario V, García-Ortiz L: Yearly evolution of organ damage markers in diabetes or metabolic syndrome: data from the LOD-DIABETES study. Cardiovasc Diabetol 2011, 10:90.

45. Johansen NB, Charles M, Vistisen D, Rasmussen SS, Wiinberg N, Borch-Johnsen K, Lauritsen T, Sandbaek A, Witte DR: Effect of intensive multifactorial treatment compared with routine care on aortic stiffness and central blood pressure among individuals with screen-detected type 2 diabetes: the ADDITION-Denmark study. Diabetes Care 2012, doi:10.2337/dc12-0176.